Graves' disease is an autoimmune condition that causes hyperthyroidism, which is an overactive thyroid gland. This condition is often associated with eye signs including proptosis, edema, and diplopia, collectively termed Graves' orbitopathy. In a clinical trial, researchers evaluated the safety and effectiveness of K1-70™, a human monoclonal TSHR (Thyroid Stimulating Hormone)-specific autoantibody that blocks ligand binding and stimulation of the receptor, in treating Graves' disease.
Clinical trial
The study involved 18 patients with Graves' disease who were stable on antithyroid drug medication. They received a single intramuscular (IM) or intravenous (IV) dose of K1-70™ during an open-label phase I ascending dose, safety, tolerability, pharmacokinetic and pharmacodynamic study. The researchers also determined the immunogenic effects of K1-70™.
The results of the clinical trial showed that K1-70™ was well-tolerated by all subjects at all doses, and no significant immunogenic response was observed. There were no deaths or serious adverse events reported. The researchers also observed an increased systemic exposure to K1-70™ following a change to IV dosing, indicating that this was the correct dosage route.
Expected pharmacodynamic effects occurred after a single IM dose of 25mg or a single IV dose of 50mg or 150mg, with fT3, fT4, and TSH levels progressing into hypothyroid ranges. Clinically significant improvements were also observed in the symptoms of both Graves' disease and Graves' orbitopathy. These included reduced tremors, improved sleep, improved mental focus, reduced toilet urgency, and reduced exophthalmos measurements and photosensitivity.